Literature DB >> 33340111

Nonalcoholic Steatohepatitis: Current Thinking From the Division of Hepatology and Nutrition at the Food and Drug Administration.

Frank A Anania1, Lara Dimick-Santos1, Ruby Mehta1, Joseph Toerner1, Julie Beitz1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33340111     DOI： 10.1002/hep.31687

Source DB:  PubMed          Journal:  Hepatology        ISSN： 0270-9139            Impact factor:   17.425


× No keyword cloud information.
  3 in total

Review 1.  Histological assessment based on liver biopsy: the value and challenges in NASH drug development.

Authors:  Xiao-Fei Tong; Qian-Yi Wang; Xin-Yan Zhao; Ya-Meng Sun; Xiao-Ning Wu; Li-Ling Yang; Zheng-Zhao Lu; Xiao-Juan Ou; Ji-Dong Jia; Hong You
Journal:  Acta Pharmacol Sin       Date:  2022-02-14       Impact factor: 7.169

2.  NASH: regulatory considerations for clinical drug development and U.S. FDA approval.

Authors:  Brian E Harvey
Journal:  Acta Pharmacol Sin       Date:  2022-01-21       Impact factor: 7.169

Review 3.  Chronic hepatitis B infection with concomitant hepatic steatosis: Current evidence and opinion.

Authors:  Yi-Wen Shi; Rui-Xu Yang; Jian-Gao Fan
Journal:  World J Gastroenterol       Date:  2021-07-14       Impact factor: 5.742
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.